Damora Therapeutics (DMRA) Cash & Equivalents (2019 - 2026)
Damora Therapeutics' Cash & Equivalents was $540.52 million in Q2 2026, compared with $10.21 million a year earlier and up 1.4% from the prior quarter.
Powered by 
Analysis
Damora Therapeutics (DMRA) Cash & Equivalents (2019 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Damora Therapeutics came in at $257.62 million.
- Cash & Equivalents shows a five-year compound annual growth rate of 9.5% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $14.18 million in FY2024 (-34.0%), $21.47 million in FY2023 (-34.5%), $32.79 million in FY2022 (-47.6%) and $62.56 million in FY2021 (-61.8%).
- The Q2 2026 figure marks the highest quarterly Cash & Equivalents in data going back to Q3 2019.
- Across the past five years, year-over-year decline in Cash & Equivalents ran from 0.4% in Q2 2024 to 61.8% in Q4 2021.
- Per Business Quant data, DMRA's Cash & Equivalents in the three quarters before Q2 2026 was $532.9 million (Q1 2026), $257.62 million (Q4 2025) and $7.61 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Damora Therapeutics | 1.27 Bn | -63.83 Mn | - | 540.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 540.52 Mn |
| Mar 31, 2026 | 532.90 Mn |
| Dec 31, 2025 | 257.62 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 10.21 Mn |
| Mar 31, 2025 | 11.94 Mn |
| Dec 31, 2024 | 14.18 Mn |
| Sep 30, 2024 | 19.68 Mn |
| Jun 30, 2024 | 22.86 Mn |
| Mar 31, 2024 | 21.09 Mn |
| Dec 31, 2023 | 21.47 Mn |
| Sep 30, 2023 | 23.08 Mn |
| Jun 30, 2023 | 22.96 Mn |
| Mar 31, 2023 | 25.07 Mn |
| Dec 31, 2022 | 32.79 Mn |
| Sep 30, 2022 | 28.34 Mn |
| Jun 30, 2022 | 29.80 Mn |
| Mar 31, 2022 | 45.39 Mn |
| Dec 31, 2021 | 62.56 Mn |
| Sep 30, 2021 | 66.16 Mn |
API Access
Damora Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=DMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "DMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=DMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();